Published in Hopkins HIV Rep on July 01, 2001
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 4.45
Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother (2000) 3.28
HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science (1988) 3.12
Vaccinia virus expression vectors. Annu Rev Immunol (1987) 2.75
Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis (1996) 1.82
Balancing justice and autonomy in clinical research with healthy volunteers. Clin Pharmacol Ther (2007) 1.68
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol (2001) 1.55
The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol (1994) 1.29
An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1990) 1.28
Effect of indomethacin and aspirin on gastric blood flow and acid secretion. J Pharmacol Exp Ther (1977) 1.25
Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly. J Virol (1998) 1.20
Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med (1996) 1.18
Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition. J Exp Med (1990) 1.17
Dextran sulfate is poorly absorbed after oral administration. Ann Intern Med (1989) 1.13
Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr (2001) 1.08
Prostaglandin and histamine involvement in the gastric vasodilator action of pentagastrin. J Pharmacol Exp Ther (1977) 1.07
Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem (2000) 1.06
The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther (1999) 0.97
Clearance of recombinant vaccinia virus expressing IL-2: role of local host immune responses. Cell Immunol (1993) 0.97
Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus. J Acquir Immune Defic Syndr (2001) 0.96
A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis (1995) 0.94
Rhesus monkey macrophages infected with simian immunodeficiency virus cause rapid lysis of CD4-bearing lymphocytes. J Gen Virol (1991) 0.92
Payment to healthy volunteers in clinical research: the research subject's perspective. Clin Pharmacol Ther (2010) 0.90
High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. J Infect Dis (1995) 0.88
HIV cure: knocking on the door. Clin Pharmacol Ther (2013) 0.88
Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother (2009) 0.87
Vaccinia virus expression vectors. Ann N Y Acad Sci (1989) 0.85
Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 0.85
Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors. Antimicrob Agents Chemother (2000) 0.83
HIV genotype and phenotype--arresting resistance? JAMA (2000) 0.83
Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (1994) 0.82
Non-Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine. JAMA (1991) 0.82
Pharmacoecology: a new name for an old science. Clin Pharmacol Ther (2008) 0.80
Post-exposure prophylaxis revisited: new CDC guidelines. Centers for Disease Control and Prevention. Hopkins HIV Rep (1998) 0.80
Combination antiretroviral therapy for HIV infection. Am Fam Physician (1998) 0.78
Herbal remedies in resource-poor settings: friend or foe? Clin Pharmacol Ther (2008) 0.78
Diagnosis of human immunodeficiency virus infection using citrated whole blood. Clin Diagn Lab Immunol (1997) 0.78
Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo. Clin Pharmacol Ther (2010) 0.78
Roles of vaccinia virus in the development of new vaccines. Vaccine (1988) 0.76
Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. J Acquir Immune Defic Syndr (2000) 0.76
Comparison of the effects of 3'-azidothymidine with those of neutralizing antibodies on simian immunodeficiency virus infection in macrophages. Antimicrob Agents Chemother (1993) 0.75
Internal medicine: cyclosporine-a powerful new immunosuppressant. West J Med (1985) 0.75
What's in a trough? Therapeutic drug monitoring and antiretroviral regimens. Hopkins HIV Rep (2000) 0.75
Fat city: understanding HIV lipodystrophy. Hopkins HIV Rep (1998) 0.75
Inactivation of human immunodeficiency virus type 1 reverse transcriptase by oltipraz: evidence for the formation of a stable adduct. Arch Biochem Biophys (1995) 0.75
Drug interactions and pharmacology. Hopkins HIV Rep (2000) 0.75
Double jeopardy: the hazards of drug-drug interactions. Res Initiat Treat Action (1998) 0.75
Complications of HIV therapy. Hopkins HIV Rep (2000) 0.75
HIV-related drug metabolism and cytochrome P450 enzymes. AIDS Clin Care (2000) 0.75
When will once (-a day) be enough? Hopkins HIV Rep (2000) 0.75
Patients, physicians, and clinical trials: the other side of the coins. J Investig Med (1999) 0.75
Drug transporter, drug concentrations, and drug interactions. Hopkins HIV Rep (2001) 0.75
Pharmacology and drug interactions: compartmentalizing antiretrovirals. Hopkins HIV Rep (2000) 0.75
Pharmacology: a progress report. Hopkins HIV Rep (1999) 0.75